NightHawk Biosciences Inc

NightHawk Biosciences, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.

The full company name is Night Hawk Entertainment Corp.

Heat Biologics

Key Corporate Updates Announced Via Livestream Event from Manhattan, Kansas, available for replay at Nighthawkbio.com Key Corporate Updates Announced Via Livestream Event from Manhattan, Kansas, available for replay at Nighthawkbio.com

Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company's Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities

News for NightHawk Biosciences Inc Stock (NHWK)